-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F/4z4RpwZ7bHvjxApc2RvoBLwjSS8P8efcF0APgMwtcicyCzlM8x/Pp0q+5i2Uup EVaIBfpUYgZbIADWxCn0Zg== 0000941302-98-000021.txt : 19980218 0000941302-98-000021.hdr.sgml : 19980218 ACCESSION NUMBER: 0000941302-98-000021 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 19980217 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNSORB BIOTECH INC CENTRAL INDEX KEY: 0001025863 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-52837 FILM NUMBER: 98541076 BUSINESS ADDRESS: STREET 1: STE 201 STREET 2: 1204 KENSINGTON RD NW CITY: CALGARY ALBERTA CANA STATE: A0 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MILLS ERIN INVESTMENT CORP CENTRAL INDEX KEY: 0001008411 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 7501 KEELE ST STE 500 STREET 2: CONCORD ONTARIO CANADA CITY: L4K 1Y2 MAIL ADDRESS: STREET 1: 7501 KEELE ST STREET 2: STE 500 CITY: CONCORD ONTARIO CANA SC 13G 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SYNSORB BIOTECH INC. - --------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.01 per share - --------------------------------------------------------------------------- (Title of Class of Securities) 87160V104 - --------------------------------------------------------------------------- (CUSIP Number) Check the following box if a fee is being paid with this statement ____. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) CUSIP No. 87160V104 13G 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS The Erin Mills Development Corporation 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ X ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada NUMBER OF 5 SOLE VOTING POWER SHARES BENEFICIALLY 6 SHARED VOTING POWER 2,450,000 OWNED BY EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON WITH 8 SHARED DISPOSITIVE POWER 2,450,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,450,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 13.1% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTIONS BEFORE FILLING OUT CUSIP No. 87160V104 13G 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS The Erin Mills Investment Corporation 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ X ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Alberta, Canada NUMBER OF 5 SOLE VOTING POWER SHARES BENEFICIALLY 6 SHARED VOTING POWER 2,450,000 OWNED BY EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON WITH 8 SHARED DISPOSITIVE POWER 2,450,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,450,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 13.1% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTIONS BEFORE FILLING OUT STATEMENT ON SCHEDULE 13G This statement on Schedule 13G relates to the common stock, par value $.01 per share ("Common Stock"), of SYNSORB Biotech Inc. (the "Company"), and is filed by The Erin Mills Development Corporation, an Ontario, Canada corporation ("EMDC"), as the indirect beneficial owner of the shares of Common Stock reported as beneficially owned in this statement, and The Erin Mills Investment Corporation, an Alberta, Canada corporation and majority owned subsidiary of EMDC ("TEMIC"), as the direct beneficial owner of the shares of Common Stock reported as beneficially owned in this statement. ITEM 1(A) NAME OF ISSUER. SYNSORB Biotech Inc. ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES. 11011 Esso Plaza East Tower 425 - 1st Street S.W. Calgary, Alberta T2P 3L8 ITEM 2(A) NAME OF PERSON FILING. This Schedule 13G is filed by The Erin Mills Investment Corporation and The Erin Mills Development Corporation. ITEM 2(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE. The address of both TEMIC and EMDC is 7501 Keele Street, Suite 500, Concord, Ontario L4K 1Y2, Canada. ITEM 2(C) CITIZENSHIP OR PLACE OF ORGANIZATION. TEMIC is incorporated under the laws of the Province of Alberta, Canada, and EMDC is incorporated under the laws of the Province of Ontario, Canada. ITEM 2(D) TITLE OF CLASS OF SECURITIES. Common Stock, par value $.01 per share. ITEM 2(E) CUSIP NUMBER. 87160V104 ITEM 3 REPORTING PERSON. Inapplicable ITEM 4 OWNERSHIP. See Items 5 through 11 on page 2 for EMDC and page 3 for TEMIC. ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. Inapplicable ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Inapplicable ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Inapplicable ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Inapplicable ITEM 9 NOTICE OF DISSOLUTION OF GROUP. Inapplicable ITEM 10 CERTIFICATION. Inapplicable EXHIBITS Exhibit 1 Joint Filing Agreement dated February ___, 1998 between TEMIC and EMDC. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 1998 THE ERIN MILLS DEVELOPMENT CORPORATION By: /S/LARRY ROBBINS ------------------------ Larry Robbins Secretary THE ERIN MILLS INVESTMENT CORPORATION By: /S/LARRY ROBBINS ------------------------ Larry Robbins Secretary EX-99 2 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $.01 per share, of SYNSORB Biotech Inc., and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings. The undersigned further agree that each party hereto is responsible for timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument. IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 13, 1998. THE ERIN MILLS DEVELOPMENT CORPORATION By: /S/LARRY ROBBINS ------------------------ Larry Robbins Secretary THE ERIN MILLS INVESTMENT CORPORATION By: /S/LARRY ROBBINS ------------------------ Larry Robbins Secretary -----END PRIVACY-ENHANCED MESSAGE-----